Managed Healthcare Executive6d
Patient Experience With Intravenous and Subcutaneous Therapies
An expert gastroenterologist dissects a study that analyzed patient experience with intravenous and subcutaneous biological therapies.
Medscape4d
FDA OKs Subcutaneous Atezolizumab Formulation for Multiple Cancer Indications
The US Food and Drug Administration (FDA) has approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc ...
Cure Today7d
FDA Approves Subcutaneous Tecentriq Formulation
Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin ...
Targeted Oncology10d
Data Shows Subcutaneous Rituximab Similar to IV in Non-Hodgkin Lymphoma
Subcutaneous and intravenous forms of rituximab showed similar efficacy in patients with non-Hodgkin lymphoma.
Medscape6d
FDA Okays Subcutaneous Ocrelizumab for MS
Subcutaneous administration of ocrelizumab was noninferior to intravenous infusion in the phase 3 OCARINA II trial.
The American Journal of Managed Care3d
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
FDA Approves Genentech’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug ...
Targeted Oncology13d
FDA Approves Ready-to-Use Subcutaneous Bortezomib Formulation
The ready-to-use formulation of bortezomib is now an FDA-approved option for patients with multiple myeloma and mantle cell ...